<p>/PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) 和 MS Pharma 聯合宣佈，他們已簽署一項獨家許可和供應協議，以在中東和北非（&#34;MENA 地區&#34;）商業化 FYB206，這是 Formycon 針對重磅藥物 Keytruda®[1]（pembrolizumab）的生物仿製藥候選藥物。該協議包括未來技術轉讓的選項。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Formycon 標誌</p>
<p>&#34;這項針對 MENA 地區的許可協議標誌着我們 Keytruda® 生物仿製藥候選藥物商業合作活動的開始。未來還將有針對其他地區和國家的進一步協議。與 MS Pharma 的合作，我們正在利用已經成功實施的 FYB201、FYB202 和 FYB203 生物仿製藥的良好合作關係。MS Pharma 是一個強大的參與者，能夠可持續地改善 MENA 地區對這一重要癌症藥物的獲取。FYB206 目前接近臨牀開發階段的結束，我們預計將在 2026 年第一季度獲得主要終點的結果，&#34; <strong>Formycon AG 的首席商務官 Nicola Mikulcik 説道。</strong></p>
<p>&#34;與 Formycon 擴大 FYB206（pembrolizumab）的合作關係，是 MS Pharma 一個戰略性的重要里程碑。這一合作不僅鞏固了我們在 MENA 地區生物仿製藥領域的領導地位，還展示了我們擴大創新癌症療法獲取的承諾。利用 Formycon 的科學專長與我們在當地的成熟能力以及我們在沙特阿拉伯的先進製造設施，我們有能力提供滿足 MENA 地區患者和醫療系統需求的高質量生物仿製藥，&#34; <strong>MS Pharma 的首席執行官 Kalle Känd 評論道。</strong></p>
<p>在協議簽署後，Formycon 將獲得一次性報酬，並有資格獲得基於某些開發和監管里程碑達成情況的進一步付款，Formycon 還將獲得該地區產生的毛利潤的顯著份額。</p>
<p>MS Pharma 將繼續為更大的治療可及性做出貢獻，同時支持專注於本地化、韌性和可持續獲取腫瘤護理的國家戰略。這一合作強化了 MS Pharma 作為該地區政府和醫療機構長期合作伙伴的角色，幫助維持患者的連續性和護理質量。</p>
<p>Pembrolizumab 是一種人源化單克隆抗體，屬於免疫檢查點抑制劑組，用於治療多種腫瘤。憑藉其在腫瘤學中的廣泛適應症和 2024 年全球銷售額達 295 億美元 [2]，Keytruda® 目前是全球最暢銷的藥物之一。在 MENA 地區，預計銷售額約為 2.4 億美元 [3]，使其成為該地區銷售最高的生物製劑，並突顯出 MENA 地區對腫瘤學的巨大需求和市場潛力。</p>
<p><em>1.</em> <em>Keytruda® 是 Merck Sharp \u0026 Dohme LLC 的註冊商標，該公司是 Merck \u0026 Co, Inc, Rahway, NJ/USA 的子公司。</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA 招標數據，截止至 2025 年 6 月。</em></p>
<p><strong>關於 Formycon：</strong></p>
<p>Formycon AG (FSE: FYB) 是一家領先的獨立高質量生物仿製藥開發公司，專注於生物製藥藥物的後續產品。該公司專注於眼科、免疫學、免疫腫瘤學和其他關鍵疾病領域的治療，覆蓋從技術開發到臨牀試驗再到監管機構批准的幾乎整個價值鏈。為了商業化其生物仿製藥，Formycon 依賴於全球範圍內強大、值得信賴和長期的合作伙伴關係。Formycon 已經在市場上推出了兩種生物仿製藥 FYB201/ranibizumab 和 FYB202/ustekinumab。另一種生物仿製藥 FYB203/aflibercept 已獲得 FDA、EMA 和 MHRA 的批准。目前有四個管線候選藥物，包括 FYB208/dupilumab，正在開發中。通過其生物仿製藥，Formycon 正在為儘可能多的患者提供高效且可負擔得起的藥物做出重要貢獻。</p>
<p>Formycon AG 總部位於慕尼黑，上市於法蘭克福證券交易所的 Prime Standard：FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY，並且是 SDAX 選擇指數的一部分。更多信息請訪問：https://www.formycon.com。</p>
<p><strong>關於 MS Pharma：</strong></p>
<p>MS Pharma 是 MENA 地區領先的製藥公司，專注於廣泛的仿製藥和生物製劑的開發、生產和分銷。公司定位於快速增長，在約旦、阿爾及利亞和沙特阿拉伯運營五個製造設施，其中包括新近啓動的生物製劑工廠，所有這些設施服務於更廣泛的 MENA 市場。公司總部位於約旦安曼，在瑞士楚格設有管理辦公室，MS Pharma 在 12 個國家僱傭超過 2000 名員工。有關更多信息，請訪問：www.mspharma.com。</p>
<p><strong>關於生物仿製藥：</strong></p>
<p>自 1980 年代引入以來，生物製藥藥物徹底改變了嚴重和慢性疾病的治療。到 2032 年，許多這些藥物將失去專利保護——包括 45 種年全球總營業額超過 2000 億美元的重磅藥物。生物類似藥是生物製藥藥物的繼任產品，其市場獨佔權已到期。它們在歐盟、美國、加拿大、日本和澳大利亞等高度監管的市場中，根據嚴格的監管程序獲得批准。生物類似藥創造了競爭，從而使更多患者能夠獲得生物製藥療法。同時，它們降低了醫療系統的成本。目前，生物類似藥的全球銷售額約為 210 億美元。分析師預計，到 2030 年，銷售額可能超過 740 億美元。</p>
<p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
<p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
<p><strong>聯繫方式：</strong> Sabrina Müller</p>
<p>投資者關係與企業傳播總監</p>
<p>Formycon AG</p>
<p>Fraunhoferstr. 15</p>
<p>82152 Planegg-Martinsried</p>
<p>德國</p>
<p>電話：+49 (0) 89 - 86 46 67 149</p>
<p>傳真：+ 49 (0) 89 - 86 46 67 110</p>
<p>[email protected]</p>
<p><strong>聯繫方式：</strong> Orayb Akeel</p>
<p>企業傳播總監</p>
<p>MS Pharma</p>
<p>約旦安曼</p>
<p>電話：+962 (0) 77- 680 1114</p>
<p>[email protected]</p>
<p><strong>免責聲明：</strong></p>
<p>本新聞稿可能包含基於 Formycon 當前預期和某些假設的前瞻性陳述和信息。各種已知和未知的風險、不確定性及其他因素可能導致實際未來結果、公司財務狀況、業績、產品發展與此處給出的估計之間存在重大差異。這些已知和未知的風險和不確定性包括但不限於研究與開發、監管批准過程、監管機構和其他政府當局的行動時機、臨牀結果、法律法規的變化、產品質量、患者安全、專利訴訟、合同風險以及對第三方的依賴。關於管線產品，Formycon AG 不提供任何陳述、保證或其他保證，確保產品將獲得必要的監管批准或證明具有商業可行性和/或成功。Formycon AG 不承擔更新這些前瞻性陳述或在發生與預期不同的發展時進行更正的義務。本文件既不構成出售的要約，也不構成購買或認購 Formycon AG 證券的要約邀請。Formycon AG 的證券不會進行公開發行，也不打算進行公開發行。本文件及其中包含的信息不得在美國、加拿大、澳大利亞、日本或任何其他禁止此類要約或邀請的司法管轄區內分發。該文件不構成在美國出售證券的要約。</p>
<p>來源 MS Pharma</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1"/></p>

<p>Formycon AG 和 MS Pharma 簽署了一項獨家許可和供應協議，以在中東和北非地區商業化 Formycon 的 Keytruda® 生物仿製藥候選產品 FYB206。該協議包括未來的技術轉讓選項，旨在改善癌症治療的可及性。Formycon 將獲得預付款和毛利潤分成，而 MS Pharma 將增強治療的可用性並支持國家醫療保健戰略</p>

<p>, /PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into an exclusive licensing and supply agreement for the commercialization of FYB206, Formycon's biosimilar candidate to the blockbuster drug Keytruda®[1] (pembrolizumab), in the Middle East and North Africa (&#34;MENA region&#34;). The agreement includes an option for future technology transfer.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Formycon AG (FSE: FYB, Prime Standard) 和 MS Pharma 聯合宣佈，他們已簽署一項獨家許可和供應協議，以在中東和北非（&#34;MENA 地區&#34;）商業化 FYB206，這是 Formycon 針對重磅藥物 Keytruda®[1]（pembrolizumab）的生物仿製藥候選藥物。該協議包括未來技術轉讓的選項。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Formycon Logo</p>
<div class="lb-trans"><p>Formycon 標誌</p>
</div><p>&#34;This licensing deal for the MENA region represents the start of the commercial partnering activities for our Keytruda® biosimilar candidate. Further agreements for additional regions and countries shall follow in due time. With MS Pharma, we are leveraging the well-established excellent collaboration that has already been successfully implemented for our biosimilars FYB201, FYB202, and FYB203. MS Pharma is a strong player that can sustainably improve access to this important cancer drug across the MENA region. FYB206 is currently approaching the end of its clinical development phase, and we expect results for the primary endpoint in the first quarter of 2026,&#34; said <strong>Nicola Mikulcik, CBO of Formycon AG</strong>.</p>
<div class="lb-trans"><p>&#34;這項針對 MENA 地區的許可協議標誌着我們 Keytruda® 生物仿製藥候選藥物商業合作活動的開始。未來還將有針對其他地區和國家的進一步協議。與 MS Pharma 的合作，我們正在利用已經成功實施的 FYB201、FYB202 和 FYB203 生物仿製藥的良好合作關係。MS Pharma 是一個強大的參與者，能夠可持續地改善 MENA 地區對這一重要癌症藥物的獲取。FYB206 目前接近臨牀開發階段的結束，我們預計將在 2026 年第一季度獲得主要終點的結果，&#34; <strong>Formycon AG 的首席商務官 Nicola Mikulcik 説道。</strong></p>
</div><p>&#34;Extending our partnership with Formycon for FYB206 (pembrolizumab), is a strategically important milestone for MS Pharma. This collaboration not only strengthens our position as a leader in biosimilars across the MENA region but also demonstrates our commitment to expanding access to innovative cancer therapies. Leveraging Formycon's scientific expertise with our established local capabilities and our advanced manufacturing facility in Saudi Arabia, we are well-positioned to deliver high-quality biosimilars that meet the needs of patients and healthcare systems in the MENA region,&#34; commented <strong>Kalle Känd, CEO of MS Pharma</strong>.</p>
<div class="lb-trans"><p>&#34;與 Formycon 擴大 FYB206（pembrolizumab）的合作關係，是 MS Pharma 一個戰略性的重要里程碑。這一合作不僅鞏固了我們在 MENA 地區生物仿製藥領域的領導地位，還展示了我們擴大創新癌症療法獲取的承諾。利用 Formycon 的科學專長與我們在當地的成熟能力以及我們在沙特阿拉伯的先進製造設施，我們有能力提供滿足 MENA 地區患者和醫療系統需求的高質量生物仿製藥，&#34; <strong>MS Pharma 的首席執行官 Kalle Känd 評論道。</strong></p>
</div><p>Upon signature of the agreement, Formycon will receive an upfront remuneration and will be eligible for further payments contingent on the achievement of certain development and regulatory milestones, Formycon will further receive a significant share of the gross profits generated in the region.</p>
<div class="lb-trans"><p>在協議簽署後，Formycon 將獲得一次性報酬，並有資格獲得基於某些開發和監管里程碑達成情況的進一步付款，Formycon 還將獲得該地區產生的毛利潤的顯著份額。</p>
</div><p>MS Pharma will continue to contribute to greater treatment availability while supporting national strategies focused on localization, resilience, and sustainable access to oncology care. This collaboration reinforces MS Pharma's role as a long-term partner to governments and healthcare institutions across the region, helping maintain continuity and quality of care for patients.</p>
<div class="lb-trans"><p>MS Pharma 將繼續為更大的治療可及性做出貢獻，同時支持專注於本地化、韌性和可持續獲取腫瘤護理的國家戰略。這一合作強化了 MS Pharma 作為該地區政府和醫療機構長期合作伙伴的角色，幫助維持患者的連續性和護理質量。</p>
</div><p>Pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is used to treat a variety of tumors. With its broad range of indications in oncology and global sales of US$ 29.5 billion in 2024[2], Keytruda® is currently one of the world's best-selling drugs. In the MENA region, estimated sales reached approximately US$ 240 million[3], positioning it as the highest-selling biologic in the region and underscoring the substantial oncology demand and market potential across MENA.</p>
<div class="lb-trans"><p>Pembrolizumab 是一種人源化單克隆抗體，屬於免疫檢查點抑制劑組，用於治療多種腫瘤。憑藉其在腫瘤學中的廣泛適應症和 2024 年全球銷售額達 295 億美元 [2]，Keytruda® 目前是全球最暢銷的藥物之一。在 MENA 地區，預計銷售額約為 2.4 億美元 [3]，使其成為該地區銷售最高的生物製劑，並突顯出 MENA 地區對腫瘤學的巨大需求和市場潛力。</p>
</div><p><em>1.</em> <em>Keytruda® is a registered trademark of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co, Inc, Rahway, NJ/USA.</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA tender data, YTD June 2025.</em></p>
<div class="lb-trans"><p><em>1.</em> <em>Keytruda® 是 Merck Sharp \u0026 Dohme LLC 的註冊商標，該公司是 Merck \u0026 Co, Inc, Rahway, NJ/USA 的子公司。</em> <em>2.</em> <em>https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2024-financial-results/Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results – Merck.com.</em> <em>3.</em> <em>IQVIA 招標數據，截止至 2025 年 6 月。</em></p>
</div><p><strong>About Formycon:</strong></p>
<div class="lb-trans"><p><strong>關於 Formycon：</strong></p>
</div><p>Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates – including FYB208/dupilumab – are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.</p>
<div class="lb-trans"><p>Formycon AG (FSE: FYB) 是一家領先的獨立高質量生物仿製藥開發公司，專注於生物製藥藥物的後續產品。該公司專注於眼科、免疫學、免疫腫瘤學和其他關鍵疾病領域的治療，覆蓋從技術開發到臨牀試驗再到監管機構批准的幾乎整個價值鏈。為了商業化其生物仿製藥，Formycon 依賴於全球範圍內強大、值得信賴和長期的合作伙伴關係。Formycon 已經在市場上推出了兩種生物仿製藥 FYB201/ranibizumab 和 FYB202/ustekinumab。另一種生物仿製藥 FYB203/aflibercept 已獲得 FDA、EMA 和 MHRA 的批准。目前有四個管線候選藥物，包括 FYB208/dupilumab，正在開發中。通過其生物仿製藥，Formycon 正在為儘可能多的患者提供高效且可負擔得起的藥物做出重要貢獻。</p>
</div><p>Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX selection index. Further information can be found at: https://www.formycon.com.</p>
<div class="lb-trans"><p>Formycon AG 總部位於慕尼黑，上市於法蘭克福證券交易所的 Prime Standard：FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY，並且是 SDAX 選擇指數的一部分。更多信息請訪問：https://www.formycon.com。</p>
</div><p><strong>About MS Pharma:</strong></p>
<div class="lb-trans"><p><strong>關於 MS Pharma：</strong></p>
</div><p>MS Pharma is a leading regional pharmaceutical company in the MENA region, specializing in the development, production, and distribution of a broad portfolio of generic and biologic therapies. Positioned for rapid growth, the company operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia – home to a newly launched biologics plant, all serving the broader MENA market. Headquartered in Amman, Jordan, with management offices in Zug, Switzerland, MS Pharma employs over 2,000 people across 12 countries. For more information, please visit: www.mspharma.com.</p>
<div class="lb-trans"><p>MS Pharma 是 MENA 地區領先的製藥公司，專注於廣泛的仿製藥和生物製劑的開發、生產和分銷。公司定位於快速增長，在約旦、阿爾及利亞和沙特阿拉伯運營五個製造設施，其中包括新近啓動的生物製劑工廠，所有這些設施服務於更廣泛的 MENA 市場。公司總部位於約旦安曼，在瑞士楚格設有管理辦公室，MS Pharma 在 12 個國家僱傭超過 2000 名員工。有關更多信息，請訪問：www.mspharma.com。</p>
</div><p><strong>About Biosimilars:</strong></p>
<div class="lb-trans"><p><strong>關於生物仿製藥：</strong></p>
</div><p>Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.</p>
<div class="lb-trans"><p>自 1980 年代引入以來，生物製藥藥物徹底改變了嚴重和慢性疾病的治療。到 2032 年，許多這些藥物將失去專利保護——包括 45 種年全球總營業額超過 2000 億美元的重磅藥物。生物類似藥是生物製藥藥物的繼任產品，其市場獨佔權已到期。它們在歐盟、美國、加拿大、日本和澳大利亞等高度監管的市場中，根據嚴格的監管程序獲得批准。生物類似藥創造了競爭，從而使更多患者能夠獲得生物製藥療法。同時，它們降低了醫療系統的成本。目前，生物類似藥的全球銷售額約為 210 億美元。分析師預計，到 2030 年，銷售額可能超過 740 億美元。</p>
</div><p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2759179/5655882/MS_Pharma_Logo.jpg</p>
</div><p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2838456/Formycon_Logo.jpg</p>
</div><p><strong>Contact:</strong> Sabrina Müller</p>
<div class="lb-trans"><p><strong>聯繫方式：</strong> Sabrina Müller</p>
</div><p>Director Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>投資者關係與企業傳播總監</p>
</div><p>Formycon AG</p>
<div class="lb-trans"><p>Formycon AG</p>
</div><p>Fraunhoferstr. 15</p>
<div class="lb-trans"><p>Fraunhoferstr. 15</p>
</div><p>82152 Planegg-Martinsried</p>
<div class="lb-trans"><p>82152 Planegg-Martinsried</p>
</div><p>Germany</p>
<div class="lb-trans"><p>德國</p>
</div><p>Tel.: +49 (0) 89 - 86 46 67 149</p>
<div class="lb-trans"><p>電話：+49 (0) 89 - 86 46 67 149</p>
</div><p>Fax: + 49 (0) 89 - 86 46 67 110</p>
<div class="lb-trans"><p>傳真：+ 49 (0) 89 - 86 46 67 110</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Contact:</strong> Orayb Akeel</p>
<div class="lb-trans"><p><strong>聯繫方式：</strong> Orayb Akeel</p>
</div><p>Corporate Communications Director</p>
<div class="lb-trans"><p>企業傳播總監</p>
</div><p>MS Pharma</p>
<div class="lb-trans"><p>MS Pharma</p>
</div><p>Amman – Jordan</p>
<div class="lb-trans"><p>約旦安曼</p>
</div><p>Tel: +962 (0) 77- 680 1114</p>
<div class="lb-trans"><p>電話：+962 (0) 77- 680 1114</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p><strong>Disclaimer:</strong></p>
<div class="lb-trans"><p><strong>免責聲明：</strong></p>
</div><p>This press release may contain forward-looking statements and information which are based on Formycon's current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.</p>
<div class="lb-trans"><p>本新聞稿可能包含基於 Formycon 當前預期和某些假設的前瞻性陳述和信息。各種已知和未知的風險、不確定性及其他因素可能導致實際未來結果、公司財務狀況、業績、產品發展與此處給出的估計之間存在重大差異。這些已知和未知的風險和不確定性包括但不限於研究與開發、監管批准過程、監管機構和其他政府當局的行動時機、臨牀結果、法律法規的變化、產品質量、患者安全、專利訴訟、合同風險以及對第三方的依賴。關於管線產品，Formycon AG 不提供任何陳述、保證或其他保證，確保產品將獲得必要的監管批准或證明具有商業可行性和/或成功。Formycon AG 不承擔更新這些前瞻性陳述或在發生與預期不同的發展時進行更正的義務。本文件既不構成出售的要約，也不構成購買或認購 Formycon AG 證券的要約邀請。Formycon AG 的證券不會進行公開發行，也不打算進行公開發行。本文件及其中包含的信息不得在美國、加拿大、澳大利亞、日本或任何其他禁止此類要約或邀請的司法管轄區內分發。該文件不構成在美國出售證券的要約。</p>
</div><p>SOURCE MS Pharma</p>
<div class="lb-trans"><p>來源 MS Pharma</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9TE4zOTI5NSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQwNDE0UFJfTkVXU19VU1BSX19fX19MTjM5Mjk1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN39295&amp;Transmission_Id=202512040414PR_NEWS_USPR_____LN39295&amp;DateId=20251204"/></p>

Formycon 與 MS Pharma 簽署了針對 MENA 地區的 Keytruda®生物類似藥候選產品 FYB206 的獨家商業化合作協議